According to the Navadhi Global Peptide Therapy Market Strategic Research Report 2026-2031 , India's emergence as both a high-growth demand market (19.89% CAGR) and a biosimilar manufacturing hub creates a unique dual role as GLP-1 costs decline through Indian biosimilar production, the addressable patient population in price-sensitive Asian and African markets will expand dramatically, driving the 21.24% volume CAGR through 2031.
Markers often correlate with outcomes
The combination of these five miRNAs achieved an area under the curve (AUC) of 0.82 for the early prediction of GDM
[DOI] [PMC free article] [PubMed] [Google Scholar] 172.Li S., Li Q., Li Y., Li L., Tian H., Sun X
Youll get ready-to-use marketing tools, real-time tracking, transparent earnings, and a dedicated team cheering you on every step of the way